Every critical check before acquiring an IVF or reproductive medicine practice — from physician retention risk to CDC outcome data and embryo consent compliance.
Acquiring a fertility clinic requires a fundamentally different due diligence framework than most lower middle market healthcare transactions. Success rates are publicly reported, physician dependency can be catastrophic if not addressed pre-close, and the regulatory environment spans CDC ART reporting, CLIA laboratory certification, state-specific corporate practice of medicine rules, and embryo disposition consent law. Buyers — whether PE-backed fertility networks, regional health systems, or entrepreneurial physicians — must simultaneously evaluate clinical quality, physician contract structure, laboratory infrastructure, and payer economics before committing capital. This checklist organizes the five highest-stakes due diligence domains for a fertility clinic acquisition in the $2M–$5M revenue range, with red flags that should trigger renegotiation or deal termination.
Evaluates dependency on key reproductive endocrinologists, contract terms, and transition stability post-close.
Review all physician employment agreements, non-competes, and post-close retention commitments.
A departing RE post-close can instantly eliminate 80–100% of patient volume and revenue.
Red flag: No non-compete or employment contract exists for the founding reproductive endocrinologist.
Assess whether any associate REs or fellows are employed and contractually bound.
Single-physician practices carry catastrophic key-person risk that most PE buyers will not accept.
Red flag: Only one board-certified RE is employed with no associate or succession pipeline in place.
Confirm board certification status and licensure for all reproductive endocrinologists.
SART membership and payer credentialing require active, unrestricted board certification.
Red flag: Any RE is operating under a restricted, expired, or lapsed medical license or certification.
Request malpractice history, claims records, and tail coverage obligations for all physicians.
Undisclosed claims create post-close liability exposure and can affect malpractice insurability.
Red flag: Prior malpractice settlements exist that were not disclosed in the seller's representations.
Validates clinical outcomes, ART reporting compliance, and the accreditation status of the in-house IVF laboratory.
Obtain last three years of SART-reported and CDC ART success rate data for all procedures.
Below-average or unpublished success rates directly suppress patient acquisition and brand value.
Red flag: Success rates are consistently below national SART averages or have never been published.
Confirm current CLIA certification and confirm it is transferable under the proposed deal structure.
IVF laboratory operations require uninterrupted CLIA certification; a lapse halts all procedures.
Red flag: CLIA certificate has lapsed, is under review, or is non-transferable in an asset purchase structure.
Review laboratory quality control logs, equipment maintenance records, and embryology staffing ratios.
Poor lab QC documentation signals operational risk and potential accreditation vulnerabilities.
Red flag: QC logs are incomplete, embryology staffing is inadequate, or no documented QC protocols exist.
Assess age, condition, and replacement cost timeline for all IVF laboratory capital equipment.
Aging incubators, cryostorage, and workstations require immediate capex that erodes post-close returns.
Red flag: Core IVF equipment is over 10 years old with no capital replacement plan or maintenance history.
Analyzes revenue quality, payer diversification, self-pay rates, and earnings normalization for accurate valuation.
Request a third-party Quality of Earnings report normalizing physician compensation and one-time items.
Owner compensation in physician practices is frequently above-market, distorting reported EBITDA.
Red flag: Seller refuses QoE or reported EBITDA collapses materially after physician comp normalization.
Analyze payer mix across self-pay, commercial insurance, and fertility benefit platforms like Progyny.
Payer concentration in one channel creates revenue volatility; diversification improves quality of earnings.
Red flag: Over 80% of revenue comes from self-pay with no employer benefit contracts or insurance agreements.
Review all insurance reimbursement contracts and fertility benefit administrator agreements for transferability.
Non-transferable payer contracts can cause immediate revenue loss at close in an asset purchase.
Red flag: Key Progyny, WINFertility, or insurance contracts contain change-of-control termination clauses.
Evaluate revenue by service line including IVF, egg freezing, PGT, donor egg, and male fertility.
Diversified service lines reduce dependency on any single procedure and support revenue resilience.
Red flag: Over 90% of revenue is generated from a single procedure with no ancillary service development.
Covers corporate practice of medicine compliance, state licensing, embryo law, and deal structure legality.
Confirm entity structure complies with state corporate practice of medicine doctrine for the deal structure.
Non-compliant structures can void the acquisition or expose the buyer to licensure and fraud risk.
Red flag: No MSO or compliant PC structure exists and the target state prohibits corporate ownership of medicine.
Review all state health department licenses, facility permits, and confirm transferability at close.
Fertility clinics require state-level facility licenses that may not automatically transfer in an asset sale.
Red flag: Any state operating license is expired, under investigation, or flagged for non-renewal.
Audit embryo disposition consent forms, storage agreements, and cryopreservation protocols for completeness.
Incomplete embryo consent documentation creates legal liability under state genetic and property law.
Red flag: Embryo storage consent forms are missing, outdated, or non-compliant with current state law requirements.
Review all outstanding litigation, patient complaints filed with state medical boards, and regulatory citations.
Undisclosed regulatory actions signal compliance culture risk and may affect licensure post-acquisition.
Red flag: Active state medical board investigations or unresolved patient complaints exist at time of close.
Evaluates privacy practices, data security posture, and patient record management for regulatory compliance.
Conduct a HIPAA Security Rule assessment covering EHR access controls, encryption, and breach history.
Fertility patient data includes genetic and reproductive health information subject to heightened privacy scrutiny.
Red flag: No formal HIPAA risk assessment has been completed in the past 24 months or breaches went unreported.
Review Business Associate Agreements with all third-party vendors handling protected health information.
Missing BAAs expose the buyer to joint OCR liability for vendor-caused data breaches post-acquisition.
Red flag: BAAs are absent for any vendor accessing patient records, including labs, billing, or EHR platforms.
Confirm compliance with state genetic privacy laws governing storage and use of embryo and genetic data.
Several states impose stricter requirements than HIPAA on genetic and reproductive health information.
Red flag: Genetic testing consent forms do not address state-specific genetic privacy law requirements.
Assess patient record retention protocols and confirm EHR system is compatible with buyer's platform.
EHR migration failure at close disrupts clinical operations and creates patient safety and billing risk.
Red flag: Patient records are stored in a legacy system with no migration path or vendor support contract.
Find Fertility Clinic Businesses For Sale
Vetted targets with diligence packages — skip the cold search.
Fertility clinics are classified as medical practices, and SBA lenders generally restrict financing for healthcare businesses where passive ownership is prohibited and physician licensure is required to operate. The MSO structure used in most fertility acquisitions further complicates SBA underwriting, making conventional or PE-backed financing the standard path.
Fertility clinics with SART membership, strong published success rates, and at least $1.5M EBITDA typically trade at 5x–9x EBITDA. Multiple drivers include above-average clinical outcomes, more than one employed RE, diversified payer mix, and an accredited in-house IVF laboratory. Single-physician practices with key-person risk trade at the low end or require earnouts.
A Management Services Organization structure separates the clinical medical practice — which must be owned by a licensed physician under most state laws — from the business operations, which the acquiring entity controls through a management services agreement. This allows PE firms and non-physician buyers to acquire a fertility clinic's economics and operations legally without violating state corporate practice of medicine prohibitions.
Buyers should require a multi-year employment agreement with the selling physician as a condition of close, structure earnout payments tied to patient retention and EBITDA, and prioritize recruiting or retaining an associate RE before or immediately after closing. Equity rollovers of 20–40% for the founding physician are the most effective tool for aligning incentives and protecting against post-close patient attrition.
More Fertility Clinic Guides
More Due Diligence Checklists
Stop cold-searching. Find signal-scored Fertility Clinic targets with seller motivation already identified.
Create your free accountNo credit card required
For Buyers
For Sellers